These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 30464688

  • 1. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
    Ezeife DA, Melosky B, Tudor R, Lin S, Lau A, Panzarella T, Leighl NB.
    Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688
    [Abstract] [Full Text] [Related]

  • 2. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M, Afatinib Compassionate Use Consortium (ACUC).
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [Abstract] [Full Text] [Related]

  • 3. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
    Tanaka H, Taima K, Itoga M, Ishioka Y, Baba K, Shiratori T, Sakamoto H, Tsuchiya J, Nakagawa H, Hasegawa Y, Yasugahira H, Okudera K, Takanashi S, Tasaka S.
    Med Oncol; 2019 May 14; 36(6):57. PubMed ID: 31089973
    [Abstract] [Full Text] [Related]

  • 4. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K.
    Cancer Chemother Pharmacol; 2018 Dec 14; 82(6):1031-1038. PubMed ID: 30276451
    [Abstract] [Full Text] [Related]

  • 5. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
    Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A, Afatinib Compassionate Use Consortium.
    Oncologist; 2014 Oct 14; 19(10):1100-9. PubMed ID: 25232040
    [Abstract] [Full Text] [Related]

  • 6. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Washio Y, Ishida T, Kogo M, Tomii K, Okuno T, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim YH, Miyakoshi C, Yoshimura K, Hirai T, Kyoto Thoracic Oncology Research Group (KTORG).
    Lung Cancer; 2019 Sep 14; 135():175-180. PubMed ID: 31446992
    [Abstract] [Full Text] [Related]

  • 7. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.
    Abdallah SM, Hirsh V.
    Curr Oncol; 2018 Jun 14; 25(Suppl 1):S9-S17. PubMed ID: 29910643
    [Abstract] [Full Text] [Related]

  • 8. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
    Ho GF, Chai CS, Alip A, Wahid MIA, Abdullah MM, Foo YC, How SH, Zaatar A, Lam KS, Leong KW, Low JS, Yusof MM, Lee EC, Toh YY, Liam CK.
    BMC Cancer; 2019 Sep 09; 19(1):896. PubMed ID: 31500587
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
    Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ, Afatinib Compassionate Use Consortium (ACUC).
    J Thorac Oncol; 2015 Jan 09; 10(1):156-63. PubMed ID: 25247337
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
    Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, Mori M, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A.
    BMC Cancer; 2021 Mar 01; 21(1):208. PubMed ID: 33648453
    [Abstract] [Full Text] [Related]

  • 11. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fukamatsu N, Fujimoto N, Aoe K, Shibayama T, Sugimoto K, Takigawa N, Hotta K, Kiura K.
    Lung Cancer; 2018 Jan 01; 115():103-108. PubMed ID: 29290249
    [Abstract] [Full Text] [Related]

  • 12. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
    Park K, Kim JS, Kim JH, Kim YC, Kim HG, Cho EK, Jin JY, Kim M, Märten A, Kang JH.
    BMC Cancer; 2021 Jul 12; 21(1):802. PubMed ID: 34253172
    [Abstract] [Full Text] [Related]

  • 13. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
    Wu TH, Hsiue EH, Lee JH, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC.
    Clin Lung Cancer; 2018 May 12; 19(3):e361-e372. PubMed ID: 29477365
    [Abstract] [Full Text] [Related]

  • 14. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Yamaguchi O, Kaira K, Mouri A, Shiono A, Hashimoto K, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Kagamu H.
    Cancer Chemother Pharmacol; 2019 May 12; 83(5):817-825. PubMed ID: 30758646
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH, Leung DK, Choy TS, Lam KO, Lam PM, Leung TW, Kwong DL.
    BMC Cancer; 2016 Feb 24; 16():147. PubMed ID: 26911310
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
    Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
    Cancer Res Treat; 2019 Apr 24; 51(2):502-509. PubMed ID: 29898592
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
    Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, Nguyen HTT, Hoang HH, Dinh DK, Le GV, Vu TT, Truong MC, Nguyen LT.
    Asian Pac J Cancer Prev; 2021 May 01; 22(5):1581-1590. PubMed ID: 34048189
    [Abstract] [Full Text] [Related]

  • 18. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
    de Marinis F, Laktionov KK, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino MR, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina GZ, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D.
    Lung Cancer; 2021 Feb 01; 152():127-134. PubMed ID: 33387727
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
    Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, Morozumi N, Ishihara S, Minato K, Hisada T.
    Lung Cancer; 2018 Dec 01; 126():41-47. PubMed ID: 30527191
    [Abstract] [Full Text] [Related]

  • 20. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
    Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T.
    Thorac Cancer; 2019 May 01; 10(5):1078-1085. PubMed ID: 31006178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.